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Abstract
Background: The aim of this study was to determine whether intermittent warm blood cardioplegia (IWC) is
associated with comparable myocardial protection compared to cold blood cardioplegia (ICC) in patients
undergoing elective vs. emergent CABG procedures.
Methods: Out of 2292 consecutive patients who underwent isolated on-pump CABG surgery using cardioplegic arrest
either with ICC or IWC between January 2008 and December 2010, 247 consecutive emergent patients were identified
and consecutively matched 1:2 with elective patients based on gender, age (<50 years, 50–70 years, >70 years) and
ejection fraction (<40 %, 40–50 %, >50 %). Perioperative outcomes and long-term mortality were compared between
ICC and IWC strategies and predictors for 30-day mortality and perioperative myocardial injury were identified in both
elective and emergent subgroups of patients.
Results: Preoperative demographics and baseline characteristics, logistic Euroscore, CPB-time, number of distal
anastomoses and LIMA-use were comparable. Aortic cross clamp time was significantly longer in the IWC-group
regardless of the urgency of the procedure (p = 0.05 and p = 0.015 for emergent and elective settings). There were no
significant differences regarding ICU-stay, ventilation time, total blood loss and need for dialysis. The overall 30-day,
1-, 3- and 6-year survival of the entire patient cohort was 93.7, 91.8, 90.4 and 89.1 %, respectively, with significantly
better outcomes when operated electively (p < 0.001) but no differences between ICC and IWC both in elective
(p = 0.857) and emergent (p = 0.741) subgroups. Multivariate analysis did not identify the type of cardioplegia as a
predictor for 30-day mortality and for perioperative myocardial injury. However, independent factors predictive of
30-day mortality were: EF < 40 % (OR 3.66; 95 % CI: 1.79–7.52; p < 0.001), atrial fibrillation (OR 3.33; 95 % CI: 1.49-7.47;
p < 0.003), peripheral artery disease (OR 2.51; 95 % CI: 1.13–5.55; p < 0.023) and COPD (OR 0.26; 95 % CI: 1.05–6.21;
p < 0.038); predictors for perioperative myocardial infarction were EF < 40 % (OR 2.04; 95 % CI: 1.32–3.15; p < 0.001),
preoperative IABP support (OR 3.68; 95 % CI: 1.34-10.13; p < 0.012), and hemofiltration (OR 3.61; 95 % CI: 2.22–5.87;
p < 0.001).
Conclusion: Although the aortic cross clamp time was prolonged in the IWC group our results confirm effective
myocardial protection under IWC, regardless of the urgency of the procedure. We suggest that intermittent warm
cardioplegia in emergent CABG setting is a low-cost alternative and safe. It is associated with similar long-term
outcomes both in elective and emergent settings compared to intermittent cold cardioplegia.
* Correspondence: mohamed.zeriouh@uk-koeln.de
†Equal contributors
1Department of Cardiothoracic Surgery, Heart Center, University of Cologne,
Kerpener Str. 62, 50937 Cologne, Germany
Full list of author information is available at the end of the article
© 2015 Zeriouh et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zeriouh et al. Journal of Cardiothoracic Surgery  (2015) 10:180 
DOI 10.1186/s13019-015-0384-9
Background
The concept of myocardial protection during cardiac
surgery have been already described in detail in the
1950s by Bigelow, who proposed to use hypothermia as
a strategy to protect the myocardium in heart surgery
[1]. In this respect, a reduction in myocardial oxygen
consumption up to 80 % can be achieved by lowering
the blood temperature up to 20 °C. However, the
disadvantage of the isolated hypothermia without an
additional usage of cardioplegia results in an incomplete
electromechanical cardiac arrest with ventricular fibrilla-
tion. Therefore, subsequent studies by Gay and Ebert
support the use of potassium-rich solution for the induc-
tion of diastolic cardiac arrest by depolarization [2]. In
addition, further development of blood cardioplegia by
Follette and Buckberg as a composition of blood and
crystalloid solution improved myocardial protection
enormously [2, 3]. Finally, the next breakthrough was
the development of normothermic blood cardioplegia in
which Calafiore has set new standards in myocardial
protection during cardiac surgery [4, 5].
Currently, a large variety of techniques for myocardial
protection is available in cardiac surgery. Most surgical
centers in the USA and west european countries prefera-
bly apply blood cardioplegia as several studies indicated
superiority of blood cardioplegia over crystalloid solu-
tions [6]. Nevertheless, the debate over the optimal
cardioplegia strategy, the way of application and tem-
perature is still under discussion [7]. Moreover, other
additional potentially cardioprotective effects on ische-
mic myocardium are discussed in the literature [8]. In
our institution intermittent blood cardioplegia is used in
coronary artery bypass grafting (CABG) patients and is
administered antegradely either as intermittent nor-
mothermic cardioplegia (IWC) according to Calafiore’s
warm blood cardioplegia or intermittent hypothermic
cardioplegia (ICC) according to Buckberg’s cold blood
cardioplegia. Nowadays, the IWC as a simple and cost-
effective method is in widespread use throughout the
world. Whereas several studies have been focused on
differences and similarities in blood cardioplegia in
elective CABG patients, there has been a lack of evi-
dence in terms of applicability of different cardioplegia
in emergent settings. The aim of the present study was
to critically examine both myocardial protection strat-
egies in patients undergoing emergent CABG and pa-
tients receiving elective CABG.
Methods
Patients
This was a retrospective study at the Heart Center of the
University of Cologne with a cohort consisting of a total
of 2292 patients who underwent isolated CABG from
January 2008 to December 2010. Of them 247 consecutive
patients were treated as an emergency and were consecu-
tively matched 1:2 with elective coronary bypass patients
based on age (<50, 50–70 or >70 years), gender and ejec-
tion fraction (<40 %, 40–50 % or >50 %). Due to several
missing values in terms of preoperative patient character-
istics and differences regarding baseline data between
elective and emergent patients, the number of elective pa-
tients with exact matching criteria reached 448. In total,
we explored two groups with a total number of 695 pa-
tients, subsequently dividing them depending on the
blood cardioplegia strategy, with 176 patients (25.3 %) re-
ceiving ICC versus 506 patients (72.8 %) receiving IWC. A
total of 13 patients were excluded after matching due to
missing variables of interest. A subgroup analysis for each
urgency status was performed. Furthermore, factors asso-
ciated with early mortality as well as independent factors
predictive of 30-day mortality in elective and emergent
settings were evaluated.
Operation technique
CABG was standardized in terms of surgical technique
and perioperative management. In brief, all operations
were performed with cardiopulmonary bypass (CPB) via
median sternotomy. CPB was implemented with arterial
cannulation of the ascending aorta and venous drainage
which was connected to the right atrium with a two-
stage venous cannula. A root suction was always placed
in the aortic root. Left and/or right internal mammary
arteries (LIMA and RIMA) and/or venous grafts were
used as graft material. Distal anastomoses were con-
nected during the total aortic cross clamp time. Prox-
imal anastomoses were performed within reperfusion
time using a partial clamping technique of the ascending
aorta. Finally, after decannulation, insertion of chest
drains and sternal closure intubated patients were trans-
ferred to the intensive care unit (ICU).
Application of cardioplegia
In terms of cardioplegia protocol in our institution, the
so called „cold induction“ and „cold reinfusion“ Buck-
berg cardioplegia is normally used. The components are
supplied separately in two bottles (400 mL and 100 mL)
and are first mixed together when needed. The induc-
tion cardioplegia solution contains: 400 mL of high
potassium concentration with KCl 34 mmol, THAM
17.45 mmol and NaCl 16.12 mmol; following substances
are added with the second 100 mL bottle: citric acid
0.45 mmol x H2O, sodium citrate 2.60 mmol x 2 H2O,
sodium hydrogen phosphate 0.47 mmol x 2 H2O and
glucose 92.42 mmol x H2O. For the reinfusion cardiople-
gia there are also two bottles that are first mixed when
needed: 400 mL low potassium concentration of KCl
16.90 mmol, THAM 18.30 mmol and NaCl 16.90 mmol.
As with induction cardioplegia, additional substances are
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added from the 100 mL bottle: citric acid 0.48 mmol, so-
dium citrate 2.73 mmol, sodium hydrogen phosphate
0.49 mmol and glucose 96.93 mmol. This concentrated
solution is diluted in a ratio 1:4 with blood to provide
oxygen, the desired pH and osmolarity. The cardioplegic
induction solution with high potassium concentration is
delivered over 4 min to initiate cardiac arrest whereas
the following reinfusion solution with lower potassium
concentration is delivered over 2 min to maintain car-
diac arrest every 15–20 min.
Cardioplegia was delivered into the aortic root imme-
diately after cross clamping ascending aorta and re-
infused into vein grafts after completion of the distal
anastomosis in patients with severely obstructed or oc-
cluded coronary arteries. In the ICC group, cardiac ar-
rest was initiated by cold induction using a mixture of
the patient’s own blood with the crystalloid Buckberg so-
lution (Dr. Franz Köhler Chemie GmbH, Germany) at a
ratio of 1 to 4 and blood flow rate of 200–300 mL/min.
Patients were receiving cold (4–6 °C) blood cardioplegia
for 4 min aiming for a potassium target dose of
20 mmol/L. In the ICC group the body temperature was
routinely cooled down to 34 °C. According to our insti-
tutional policy there was no additional topical cooling.
While the aorta was cross clamped, intermittent re-
infusions for 2–4 min each with ICC were applied at in-
tervals of 15–20 min. Despite recommendations by the
Buckberg protocol warm terminal reperfusion (‘hot
shot’) was not infused prior to aortic unclamping in our
center. Over the study period a total of 8 surgeons were
performing elective and emergent CABG. Whereas 3
surgeons were advocates of Buckberg cardioplegia (ICC),
other 5 surgeons were proponents of Calafiore cardio-
plegia (IWC). There were no surgeons who had used
both types of cardioplegia dependent on clinical factors.
Also, as it is a retrospective analysis, the choice of cardi-
oplegia could not be influenced.
According to our institutional policy the body
temperature using IWC was maintained between 36 °C
and 37 °C. In the IWC group, infusion of normothermic
(37 °C) oxygenated blood was administered to the aortic
root using a standardized setup. A syringe pump was
connected to the extracorporeal circulation containing a
modified mixture of 30 mL of KCl (2 mmol/L) and
10 ml of MgSO4 (2 mmol/L). Cardiac arrest was in-
duced by a syringe pump with the flow rate of 150 mL/h
at a blood flow rate of 200–300 mL/min for approxi-
mately 2 min with the aim to achieve potassium concen-
tration of 20 mmol/L and magnesium target dose of
5 mmol/L. In cases when cardiac arrest was not achieved
immediately, an additional bolus injection of 3–4 ml car-
dioplegia was infused. Thereafter, the cardioplegic solu-
tion was repeatedly administered every 15 min or after
completion of each distal anastomosis, whereby the flow
rate of the syringe pumps was reduced (120-90-60 mL/h)
according the protocol of Calafiore et al. [5].
Data collection
All data were collected from our institutional database.
The Electronic Patient Record of our department con-
tains all patient data, such as demographics, preoperative
risk factors, intra- and postoperative data. Moreover, the
preoperative medication, especially the use of aspirin
and clopidogrel and their discontinuation were recorded.
In addition, laboratory values were obtained from the
institutional database.
Definitions
Thirty day mortality was defined as death of any cause
within 30 days after CABG. Perioperative myocardial in-
farction (PMI) was defined as the combination of the two
following criteria proposed by Liakopoulos et al. [8] higher
than fivefold increase in creatine kinase MB (CK-MB >120
U/L) including CK-MB fraction range of 6–25 % and an
increase in Troponin T over 1.5 ng/mL within 72 h after
surgery. Further studies have also shown that those
laboratory tests are qualified for the diagnostics of PMI in
patients undergoing cardiac surgery, especially Troponin
T [10–12].
Statistical analysis
Statistical analysis was performed using the IBM SPSS
statistics version 19 (SPSS Inc., Chicago, IL, USA). Con-
tinuous variables were expressed as mean ± standard de-
viation and categorical variables given as absolute values
and percentages. A comparison of the two groups was
done using ANOVA for continuous variables and Chi
square test or Fisher exact test for categorical variables.
P values of < 0.05 were considered statistically signifi-
cant. Univariate analysis was executed to demonstrate
associations between outcome and perioperative vari-
ables. Binary logistic regression analysis was performed
to detect independent predictors for 30-day mortality.
Kaplan-Meier Survival analysis was performed with the
view to presenting long-term outcomes of the entire
patient cohort as wall as comparing outcomes in
subgroups.
Results
Patient demographics and preoperative baseline charac-
teristics are listed in Table 1. There were no statistically
significant differences between ICC and IWC groups ex-
cept for proportion of patients on regular statin medica-
tion (66.7 % in the ICC group vs. 80.7 % in the IWC
group, p = 0.035) in the emergent subgroup and with the
presence of left main disease with more than 50 % sten-
osis (34.5 % in the ICC group vs. 23.5 % in the IWC
group, p = 0.026) in the elective subgroup. Patients were
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comparable in terms of past medical history, cardiac risk
factors, preoperative medication and logistic Euroscore.
Table 2 represents intra-operative patient data for both
groups. In the emergent subgroup, patients receiving
IWC had longer cross clamp time (41.1 ± 13.9 vs.
35.4 ± 12.2 min, p = 0.005), whereas patients receiving
ICC were associated with significantly longer administra-
tion time (5.9 ± 2,2 vs. 5.0 ± 2.7 min, p = 0.017) and
amount (329 ± 155 vs. 18.5 ± 5.6 ml, p < 0.001) of cardio-
plegia compared to IWC group. Similar associations were
also found within the elective subgroup. In terms of intra-
operative data within both subgroups there were no sta-
tistically significant differences in CPB, operation and,
reperfusion time, and the usage of IMA. Groups were
also comparable regarding phosphodiesterase-III-inhibitor
usage, and the need for hemofiltration.
Postoperative patients’ characteristics are presented in
Table 3. The mean number of platelet units transfused
in the elective subgroup was 0.62 ± 1.43 in the ICC
group and 0.31 ± 0.72 in the IWC group (p = 0.003). The
30-day all cause mortality in the elective subgroup
tended to be increased in the IWC group with 2 % in
contrast to 0 % in ICC group, however it did not reach
statistical significance (p = 0.072). Similarly, in the emer-
gent subgroup, the 30-day mortality was 5,1 % in the
ICC group vs. 4,2 % in the IWC group not reaching stat-
istical significance. During cardiac surgery in the emer-
gent subgroup 10.8 % patients of the ICC group received
an intra-aortic balloon pump (IABP) compared to 6.5 %
of the IWC group also not reaching statistical sig-
nificance (p = 0.077). Further outcome variables, such as
PMI, length of hospital and ICU stay, ventilation dur-
ation, extracorporeal membrane oxygenation (ECMO),
dialysis, inotropic support, blood transfusion and total
blood loss were also not statistically different. Long-term
outcomes in terms of overall cumulative survival are
presented in Figure 1. The overall 30-day, 1-, 3- and
6-year survival of the entire patient cohort was 93.7,
91.8, 90.4 and 89.1 %, respectively, with significantly
better outcomes when operated electively (p < 0.001)
but no differences between ICC and IWC both in elective
(p = 0.857) and emergent (p = 0.741) subgroups.
Univariate regression analysis was executed (Tables 4
and 5), in order to show possible associations of early
Table 1 Preoperative data, emergent vs. elective CABG devided in ICC and IWC
Emergent CABG Elective CABG
ICC IWC ICC IWC
n % n % p-Wert n % n % p-Wert
Age > 70 23 36.5 63 36.2 45 39.8 117 35.2
Female gender 14 22.2 36 20.7 0.857 24 21.2 71 21.4 1.000
HT 49 27.8 142 28.2 0.450 105 59.7 295 58.3 0.279
Pulm. HT 6 9.5 11 6.5 0.410 4 3.5 12 3.6 1.000
Hyperlipidemia 46 73.0 12 65.1 0.276 92 81.4 261 78.6 0.592
Diab. mellitus 16 25.4 58 33.5 0.269 38 33.6 134 40.4 0.220
BMI > 30 14 22.2 43 24.7 0.734 42 37.2 98 29.5 0.159
AF 14 23.7 33 22.2 0.857 5 4.4 20 6.0 0.641
3 V-CAD 50 79.4 136 78.2 1.000 97 85.8 274 82.5 0.467
LMS 31 49.2 81 47.1 0.883 39 34.5 78 23.5 0.026
COPD 4 6.3 20 11.6 0.332 15 13.3 35 10.5 0.490
PAD 10 15.9 31 17.9 0.847 20 17.7 52 15.7 0.658
Smoker 30 47.6 91 52.9 0.556 46 40.7 137 41.3 1.000
Crea >2 5 7.9 11 6.3 0.770 2 1.8 11 3.3 0.317
CVA 8 12.7 31 18.0 0.429 12 13.3 57 17.2 0.377
Beta-blocker 48 76.2 139 81.3 0.462 86 76.1 274 82.5 0.165
Statin 42 66.7 138 80.7 0.035 92 81.4 256 77.1 0.359
Antiplatel. 55 91.7 156 94.5 0.532 26 23.0 54 16.3 0.120
EF < 40 % 23 36.5 48 27.6 33 29.2 97 29.2
Euroscore Logistic 29.82 ± 27.14 25.09 ± 23.95 0.214 7.26 ± 10.91 7.20 ± 9.48 0.953
Preoperative Data: emergent- vs. elective CABG devided in intermittent cold cardioplegia (ICC) and intermittent warm cardioplegia (IWC) accordingto Buckberg
and Calafiore, respectively. Arterial fibrillation (AF), 3 vessel-coronary artery disease (3 V-CAD), cerebrovascular accident(CVA), Hypertension (HT), left main stenosis
(LMS), peripherial artery disease (PAD)
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clinical outcome with determined variables. There were
no associations found between each clinical endpoint
and the application of IWC or ICC.
In order to detect independent preoperative predictors
for 30-day mortality and PMI binary logistic regression
analysis was performed (Table 6 and 7) using only
preoperative variables. Multivariate analysis revealed that
EF < 40 % was the strongest independent predictor for
30-day mortality (OR 3.66; 95 %-CI 1.79-7.52; p < 0.001),
followed by atrial fibrillation, PAD and anti-platelet
drugs not suspended at least 5 days before surgery
(Table 6). In contrast, three independent predictor
Table 3 Postoperative data, emergent vs. elective CABG devided in ICC and IWC
Emergent CABG Elective CABG
ICC IWC ICC IWC
n % n % p-value n % n % p-value
30 day mortality 9 5.1 31 4.7 0.661 0 0.0 10 2.0 0.072
PMI 12 6.8 28 U 0.563 13 7.4 31 6.1 0.584
ICU(d) 6.44 ± 11.80 5.73 ± 5.70 0.536 3.83 ± 4.15 4.01 ± 4.50 0.708
Hospital (d) 13.19 ± 12.77 13.53 ± 9.39 0.825 12.98 ± 7.21 13.05 ± 6.20 0.979
Duration of ventilation (h) 109.85 ± 171.87 76.85 ± 150.32 0.194 44.45 ± 168.25 30.97 ± 73.03 0.24/
IABP
- preop 10 5.7 19 3.8 0.370 1 0.6 2 0.4 1.000
- intraop 19 10.8 33 6.5 0.077 2 1.1 8 1.6 1.000
- postop 3 1.7 9 1.8 1.000 1 0.6 5 1.0 1.000
ECMO 5 2.8 11 2.2 0.770 0 0.0 0 0.0
Blood transfusion
- RBC 7.76 ± 12.92 5.96 ± 7.30 0.183 3.93 ± 5.79 3.45 ± 5.07 0.401
- FFP 4.43 ± 6.8 2.79 ± 4.21 0.210 1.50 ± 3.95 1.19 ± 3.29 0.411
- Platelets 1.46 ± 1.45 1.05 ± 1.10 0.220 0.62 ± 1.43 0.31 ± 0.72 0.003
Total blood loss (ml) 1537.81 ± 1049.81 1400.17 ± 1019.14 0.425 1085.00 ± 715.66 962.03 ± 622.91 0.084
Dialysis 3 1.7 21 4.2 0.142 3 1.7 11 2.2 1.000
Inotropie support > 24 h 14 8.9 48 10.1 0.858 23 14.6 56 11.7 0.390
Inotropie support > 48 h 17 10.8 58 12.2 0.734 12 7.6 52 10.9 0.274
Postoperative patients data: emergent- vs. elective CABO devided in intermittent cold cardioplegia (ICC) and Intermittent warm cardioplegia (IWC). Extra Corporeal
Mrrubianr Onygrri.ition (ECMO), inti.i aortic balloon pump countrrpuKation (IABP), prfimycK.irdi.il infarction (PMI)
Table 2 Intraoperative data, emergent vs. elective CABG devided in ICC and IWC
Emergent CABG Elective CABG
ICC IWC ICC IWC
n % n % p-Wert n % n % p-Wert
AOX (min) 35.38 ± 12.16 41.05 ± 13.91 0.005 39.92 ± 12.65 43.96 ± 15.85 0.015
CBP (min) 81.81 ± 37.75 90.50 ± 38.68 0.121 77.96 ± 25.20 82.93 ± 32.25 0.138
OP-time (min) 182.03 ± 46.10 198.52 ± 64.67 0.064 184.39 ± 46.24 201.31 ± 95.14 0.092
Number of distal grafts 2.94 ± 0.76 3.09 ± 0.91 0.245 3.01 ± 0.84 2.93 ± 0.78 0.386
LIMA use 58 92.1 158 90 1.000 107 94.7 315 94.9 1.000
RIMA use 7 11.1 27 15.5 0.530 28 24.8 83 25.0 1.000
Reperfusion time (min) 34.87 ± 22.05 38.35 ± 27.35 0.366 28.54 ± 12.69 30.72 ± 17.55 0.225
Cardioplegia time (min) 5.91 ± 2.22 5.01 ± 2.68 0.017 7.03 ± 3.05 5.08 ± 2.73 0.000
Cardioplegia in (mL) 329.02 ± 155.43 18.54 ± 5.6 0.000 370 ± 125.60 19.15 ± 21.51 0.000
Hemofiltration 22 34.9 48 27.6 0.333 13 11.5 37 11.1 1.000
PDI (Corotrop) 21 34.4 63 36.4 0.877 13 15.9 75 22.6 0.143
Intraoperative patients data: emergent- vs. elective CABG devided in intermittent cold cardioplegia (ICC) and intermittent warm cardioplegia (IWC). Aortic clamp
time (AOX), cardiopumonary bybass (CBP), LIMA (left internal mammary artery), RIMA (right internal mammary artery), phospodiesterase inhibitor (PDI)
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variables showed a protective influence on 30-day mor-
tality, namely 3-vessel-disease (OR 0.36; 95 %-CI 0.16-083;
p = 0.016), preoperative statin therapy and dyslipidemia.
The strongest independent predictor for PMI ap-
peared to be preoperative anti-platelet drug therapy
(OR 4.79; 95 %-CI 3.10-7.40; p < 0.001), followed by IABP,
hemofiltration, EF < 40 %, atrial fibrillation and cerebro-
vascular disease (Table 7). Preoperative statin therapy
tended to be a borderline predictor with a protective influ-
ence on PMI (OR 0.66; 95 %-CI 0.41-1.08; p = 0.101).
Analysis of cause of death
In the IWC and ICC emergent CABG group 8 patients
vs. 5 patients died after acute myocardial infarction with
postcardiotomy ECMO, 2 of them had cerebrovascular
events, 4 patients vs. 1 patient died due to severe sepsis
with multiorgan failiure, 2 patients vs 0 patients with
mesenterial ischemia and laparotomy, 1 patients vs. 0
patients with LV and LA thrombus in association with
heparin induced thrombocytopenia and 6 patients vs. 3
patients died postoperatively after CPR due to electro-
mechanical dissociation and low-output syndrome,
respectively.
On the other hand, in the IWC and ICC elective
CABG group 3 patients vs. 0 patients died after pericar-
dial tamponade or pulmonary emboli with postcardiot-
omy ECMO, 3 patients vs. 0 patients died due to severe
sepsis and multiorgan failiure, 1 patient vs 0 patients
after mesenterial ischemia and laparotomy in association
with sepsis and 3 patients vs. 0 patients postoperatively
after CPR due to electromechanical dissociation and
low-output syndrome, respectively.
Fig. 1 Long-term overall cumulative survival of the entire patient cohort with 30-day, 1-, 3- and 6-year survival of 93.7, 91.8, 90.4 and 89.1 %,
respectively (left upper graph); significantly better outcomes when operated electively (p < 0.001, right upper graph); no differences between
ICC and IWC groups both in elective (p = 0.857, left lower graph) and emergent (p = 0.741, right lower graph) subgroups
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Table 4 Univariate analysis, primary endpoint: 30-days mortality
Univariate analysis, primary endpoint: 30-days mortality (n = 45)
Variable Yes No O.R. 95 %-C.I. p-value
n % n %
Age > 70 y 17 37.8 28 6.4 1.04 (0.56 – 1.95) 0.875
Female 13 28.9 32 5.9 1.55 (0.79 – 3.03) 0.192
HT 35 79.5 9 9.9 0.55 (0.26 – 1.22) 0.163
pulmonal. HT 7 16.3 36 5.5 4.44 (1.81 – 10.89) 0.003
HLP 21 47.7 23 13.4 0.27 (0.15 – 0.51) <0,001
Diab. mellitus 18 40.0 27 6.1 1.18 (0.64 – 2.19) 0.632
BMI > 30 13 28.9 32 6.5 1.01 (0.52 – 1.96) 1.000
AF 15 34.1 29 4.8 4.60 (2.34 – 9.03) <0,001
3 V–CAD 32 71.1 13 10.1 0.54 (0.27 – 1.05) 0.074
LMS 20 44.4 25 5.4 1.63 (0.89 – 3.00) 0.141
COPD 9 20.0 36 5.8 2.13 (0.99 – 4.62) 0.080
PAD 15 33.3 30 5.2 2.62 (1.36 – 5.03) 0.007
Smoker 22 50.0 22 5.7 1.27 (0.59 – 2.33) 0.531
Crea >2 6 14.0 37 5.7 4.32 (1.66 – 11.24) 0.007
Renal insuff. preop. Crea <2 23 51.1 22 4.7 2.25 (1.23 – 4.14) 0.013
CVA 6 13.6 38 6.6 0.79 (0.33 – 1.91) 0.333
Beta–blocker 27 62.8 16 11.8 0.38 (0.20 – 0.73) 0.005
Statin 22 51.2 21 13.6 0.27 (0.14 – 0.51) <0,001
Antiplatelet 29 67.4 14 3.6 2.90 (1.50 – 5.59) <0,001
EF < 40 % 30 66.7 15 3.1 5.36 (2.82 – 10.21) <0,001
EF 40–50 % 8 17.8 37 7.0 0.70 (0.32 – 1.53) 0.466
EF >50 % 7 15.6 38 10.4 0.19 (0.08 – 0.43) <0,001
Euroscore > =6 40 95.2 2 0.6 16.98 (4.07 – 70.85) <0,001
IABP preop. 6 13.3 39 5.9 3.68 (1.43 – 9.45) 0.013
NYHA III + IV 34 75.6 11 3.3 2.96 (1.48 – 5.94) 0.002
Emergent CABG 34 75.6 11 2.5 6.43 (3.15 – 12.76) <0,001
preop. myocardial infarction 22 50.0 22 4.4 3.26 (1.76 – 6.06) <0,001
Time between angiography and operation:
<3d 27 65.9 14 3.2 4.41 (2.26 – 8.60) <0,001
<24 h 26 63.4 15 3.1 5.79 (2.99 – 11.24) <0,001
OP–time after 08.00 pm 6 13.3 39 6.2 1.57 (0.64 – 3.86) 0.292
ICC cardioplegia 10 23.8 32 6.3 0.89 (0.43 – 1.86) 0.857
IWC cardioplegia 31 73.8 11 6.2 0.99 (0.48 – 2.00) 1.000
AoX < 80 min 37 88.1 5 35.7 0.11 (0.03 0.33) 0.001
AoX > 60 min 6 14.3 36 5.9 1.39 (0.57 – 3.43) 0.444
AoX >45 min 13 31.0 29 6.3 0.91 (0.46 – 1.78) 0.866
CPB >180 min 10 22.7 34 5.0 37.82 (12.25 116.80) <0,001
CPB > 120 min 20 45.5 24 3.9 9.36 (4.85 – 18.04) <0,001
OP–time > 180 min 33 73.3 12 3.9 2.47 (1.25 – 4.88) 0.008
Reperfusion time > 60 min 17 39.5 26 4.1 13.40 (6.57 – 27.34) <0,001
Hemofiltration 27 60.0 IS 3.2 8.54 (4.53 – 16.10) <0,001
PDI (Corotrop) 24 54.5 20 2.9 3.71 (2.00 – 6.90) <0,001
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Discussion
As several clinical studies have shown superior outcomes
when using blood cardioplegia, this type of myocardial
protection has been increasingly implemented in most
centers including our department [6, 13]. So far, most
prior research has been particularly focused on cold and
warm blood cardioplegia in elective CABG patients [14,
15]. Also the differences between crystalloid and cold
blood cardioplegia have been largely debated in previous
research [16, 17]. In order to fill the gap in terms of ana-
lysis of differences in cold and warm blood cardioplegia
in emergent setting, we conducted our study with par-
ticular attention to emergent CABG patients analysing
the impact of different intermittent blood cardioplegia
application. Previous research has indicated that there
were no significant differences between antegrade and
retrograde application of blood cardioplegia in terms of
mortality and myocardial infarction [14, 18]. Due to
easier technical aspects it has become the standard of
care to administer antegrade blood cardioplegia for
CABG procedures in our institution. In this study we
analyzed different cardioplegia strategies in emergent
compared to elective CABG patients. The intraoperative
patient data showed similar results referring to CPB, op-
eration, and reperfusion time, usage of IMA and the
need for hemodialysis. However, it is interesting to note
that even though the aortic cross clamp time was sig-
nificantly longer in the IWC group there were no
differences in PMI. In a recent study it was even sug-
gested that cold blood cardioplegia seems to be associ-
ated with more harmful effects on the myocardium in
CABG patients when compared to warm blood cardio-
plegia [19]. In contrast, another study by Liakopoulos et
al. demonstrated that cold blood cardioplegia according
to Buckberg provided superior myocardial protection in
terms of 30-day mortality, cardiac death and PMI in pa-
tients requiring prolonged aortic cross clamp time dur-
ing cardiac surgery [9]. However, it is very doubtful as to
whether a meaningful comparison can be made between
CABG and non-CABG surgery procedures precisely be-
cause severe coronary stenosis may impair cardioplegic
delivery leading to a different delivery of each solution
beyond the stenosis.
Another study with prospective randomized design
which was published two decades ago showed strong
evidence that warm blood cardioplegia was superior to
cold blood cardioplegia in CABG patients in terms of
PMI [20]. As it was a randomized study, there were sev-
eral exclusion criteria, such as patients with renal failure,
or emergent patients who were not able to sign in-
formed consent. In order to present a real world expe-
rience, we did not intend to exclude any cases, analyzing
consecutive patients including those requiring preopera-
tive mechanical ventilation or patients with renal failure.
Moreover, an emergent subgroup was created and
matched with consecutive patients from the elective
Table 4 Univariate analysis, primary endpoint: 30-days mortality (Continued)
PMI 36 80.0 9 1.7 14.71 (6.92 – 31.26) <0,001
ICU > 3d 29 69.0 13 3.3 3.28 (1.67 – 6.43) <0,001
ICU > 5d 19 45.2 23 4.6 2.52 (8.83 – 34.82) 0.006
ICU > 7d 16 38.1 26 4.8 2.59 (1.35 – 4.97) 0.005
ICU > 10d 12 28.6 30 5.1 3.13 (1.53 – 6.38) 0.003
Hospital stay > 15 d 10 22.7 34 6.3 1.07 (0.51 – 2.21) 0.851
Ventilation time >48 h 23 62.2 14 2.6 11.23 (5.54 – 22.73) <0,001
IABP preop. 27 60.0 18 2.9 15.91 (8.25 – 30.67) <0,001
ECMO 15 33.3 30 4.4 107.83 (29.61 – 392.72) <0,001
Blood transfusion 43 100.0 0 0.0 0.92 (0.90 – 0.94) 0.068
RBC Unit >5 31 68.9 14 2.7 8.48 (4.39 – 16.39) <0,001
Total blood loss >1l 19 65.6 10 2.7 2.62 (1.20 – 5.73) 0.020
Total blood loss >2l 12 41.4 17 3.0 6.17 (2.82 – 13.52) <0,001
Dialysis 12 26.7 33 5.0 8.08 (3.77 – 12.30) <0,001
Inotropie support >48 h 26 89.7 3 0.8 12.19 (3.65 40.70) <0,001
ACT > 150 sec 10 41.7 14 3.1 4.33 (1.85 – 10.10) <0,001
Pneumonia 10 22.7 34 5.1 12.39 (5.19 – 29.62) <0,001
Wound infection 3 6.8 41 6.5 0.77 (0.23 – 2.57) 1.000
Operative re–exploration 13 29.5 31 4.8 6.91 (3.34 – 14.31) <0,001
Pre-rintra- and postoperative data in univariate analysis. The nominal variables are shown in absolute and percentage figures. Cerebrovascular accident (CVA),
3 vessel coronary artery disease (3-V CAD), left main stenosis (LMS), Red blood cells (RBC)
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Table 5 Univariate analysis, primary endpoint: Perimyocardial Infarction (PMI)
Univariate analysis, primary endpoint: PMI (n = 175)
Variable Yes No O.R. 95 %-C.I. p-value
n % n %
Age > 70 years 66 (37.7) 109 (24.8) 1.05 (0.74 – 1.50) 0.786
Female 36 (20.6) 139 (25.4) 0.94 (0.62 – 1.44) 0.832
HT 141 (S1.0) 33 (35.3) 0.54 (0.34 – 0.85) 0.013
pulmonal HT 14 (8.1) 158 (24–2) 2.19 (1.08 – 4.44) 0.040
HLP 122 (70.1) 52 (30.2) 0.71 (0.48 – 1.04) 0.085
Diab. mellitus 63 (36.0) 112 (25.4) 0.98 (0.69 – 1.40) 0.928
BMI >30 50 (2S.6) 125 (25.3) 0.99 (0.68 – 1.44) 1.000
AF 39 (22.9) 131 (21.6) 3.46 (2.14 – 5.58) <0,001
3 V–CAD 140 (SO.O) 35 (27.1) 0.88 (0.57 – 1.36) 0.575
LMS 73 (42–5) 100 (21.8) 1.67 (1.17 – 2.38) 0.005
COPD 20 (H–4) 155 (25.2) 1.04 (0.61 – 1.79) 0.890
PAD 39 (22.3) 136 (23.7) 1.57 (1.02 – 2.41) 0.048
Smoker 84 (48.3) 90 (23.4) 1.23 (0.87 – 1.73) 0.253
Crea >2 14 (8–5) 151 (23.3) 3.08 (1.45 – 6.52) 0.006
Renal insuff. preop Crea <2 78 (44.6) 97 (20.8) 1.97 (1.38 – 2.80) <0,001
CVA 36 (20.7) 138 (23.9) 1.47 (0.95 – 2.28) 0.098
Beta–blocker 127 (73.4) 46 (33.3) 0.58 (0.39 – 0.87) 0.011
Statin 117 (57.6) 55 (96.4) 0.49 (0.33 – 0.72) <0,001
Antiplatelet 127 (75.1) 42 (10.9) 6.19 (4.17 – 9.19) <0,001
EF < 40 % SO (46.0) 94 (19.3) 2.66 (1.85 – 3.80) <0,001
EF 40–50 % 51 (29.3) 123 (23.1) 1.54 (1.05 – 2.27) 0.038
EF >50 % 43 (24.7) 131 (35.7) 0.27 (0.19 – 0.40) <0,001
Euroscore > =6 138 (S2.6) 29 (9.9) 5.13 (3.31 – 7.93) <0,001
IABP preop 25 (144) 149 (22.6) 12.25 (5.20 – 28.88) <0,001
NYHA 111 + IV 116 (55.3) 59 (17.9) 2.12 (1.49 – 3.04) <0,001
Emergent CABG 125 (71.4) 50 (11.2) 8.16 (5.55 – 11.99) <0,001
Time between angiography and operation
<3d 100 (65.8) 52 (11.9) 6.61 (4.45 – 9.82) <0,001
<24 h 92 (50.5) 52 (12.4) 8.77 (5.83 – 13.19) <0,001
OP–time after 08.00 pm 35 (20.0) 60 (22.2) 4.22 (2.49 – 7.15) <0,001
ICC 47 (28.0) 121 (23.9) 1.16 (0.79 – 1.72) 0.477
IWC 120 (71.4) 48 (27.1) 0.84 (0.57 – 1.23) 0.363
AoX < 80 min 164 (95.5) 5 (42.9) 0.43 (0.15 1.25) 0.122
AoX > 60 min 17 (10.0) 153 (25.0) 0.88 (0.50 – 1.56) 0.777
AoX > 45 min 53 (31.2) 117 (25.4) 0.90 (0.62 – 1.30) 0.574
CPB > 180 min 13 (7.5) 161 (23.8) 20.83 (4.65 – 93.29) <0,001
CPB > 120 min 42 (24.1) 132 (21.3) 5.00 (3.03 – 8.26) <0,001
OP–time > 180 min 111 (54 2) 62 (20.3) 1.75 (1.23 – 2.51) 0.002
Reperfusion time > 60 min 35 (20.5) 136 (21.2) 10.83 (5.47 – 21.43) <0,001
Hemofiltration 59 (39.4) 106 (18.6) 5.49 (3.64 – 8.29) <0,001
PDI (Corotrop) 81 (53.2) 92 (18.1) 3.64 (2.51 – 5.26) <0,001
30–days mortiality 36 (20.6) 139 (21.4) 14.71 (6.92 – 31.25) <0,001
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subgroup in order to provide the full analysis in patients
with different risk profiles. Additionally, compared to
the study by Warm Heart Investigators where cardiople-
gia was given antegradely and/or retrogradely depending
on surgeon’s preference this potential bias is not present
in our study as cardioplegia was always administered
antegradely [20]. Similar to our report, another study by
Calafiore et al. investigated 500 consecutive CABG pa-
tients who received IWC compared to ICC [5]. However,
the blood cardioplegia in that study was given antegra-
dely in all cases, the main difference to our study is that
Calafiore et al. only included elective CABG patients.
Interestingly, Calafiore et al. found that the outcome in
the IWC group was superior to the ICC group in terms
of requirement for circulatory assistance, IABP, and inci-
dence of myocardial infarction and cerebrovascular acci-
dents. In another prospective randomized trial Franke et
al. also showed a significantly improved myocardial pro-
tection in the IWC group compared to ICC group in
elective setting [15]. Surprisingly, there is only one ex-
perimental animal study which showed that IWC is su-
perior to ICC in ischemic myocardium [21]. Despite the
fact that the concept of myocardial protection in the be-
ginning of cardiac surgery was recommended with intro-
duction of hypothermic crystalloid cardioplegia it has
been continuously adjusted and improved by pharmaco-
logical additives, blood cardioplegia and different
application techniques [22]. Despite the fact that warm
and cold cardioplegia resulted in similar 30-days and
long-term mortality in our study, there has been a sub-
stantial amount of research showing that warm car-
dioplegia reduces several adverse post-operative events
[7, 23]. However, totally different results were found in a
meta-analysis with a total of 41 randomized controlled
trials including 5879 patients comparing warm vs. cold
cardioplegia. This study demonstrated no statistically
significant differences in the incidences of clinical events
[24]. Hence, our results seem to support this theory that
there are no statistically significant differences in using
cold vs. warm blood cardioplegia in emergent CABG pa-
tients particularly those with aortic cross clamp time less
than 60 min according to the mean cross clamp time re-
sults of our study. Additionally, we performed a multi-
variate analysis which further showed that the type
cardioplegia is not an independent predictor for PMI or
30-day mortality independent of the procedure urgency.
In terms of our additional findings suggesting pre-
operative risk factors for PMI the strongest independent
predictor appeared to be preoperative use of anti-
platelet drugs also supported by Micelli et al. demon-
strated previously [25]. Our further findings on predic-
tors of early mortality, such as decreased EF of less than
40 %, AF and PAD are also consistent with previous re-
search [26, 27]. Whereas van Straten et al. found
Table 5 Univariate analysis, primary endpoint: Perimyocardial Infarction (PMI) (Continued)
ICU > 3d 118 (72.0) 46 (11.8) 5.27 (3.58 – 7.76) <0,001
ICU > 5d 36 (52.4) 78 (15.6) 5.18 (3.54 – 7.59) <0,001
ICU > 7d 72 (43.9) 92 (17.1) 5.30 (3.55 – 7.93) <0,001
ICU > 10d 46 (32.0) 118 (19.9) 4.87 (3.03 – 7.83) <0,001
Hospital stay > 15 d 55 (32.0) 117 (21.7) 2.11 (1.42 – 3.11) <0,001
Ventilation time >48 h 72 (47 4) 80 (14.6) 14.49 (8.86 – 23.71) <0,001
IABP perioperativ 83 (47.4) 92 (15.0) <0,001
ECMO 18 (10.3) 157 (23.2) <0,001
Blood transfusion 156 (97.6) 4 (7.5) 4.37 (1.55 – 12.30) 0.001
EK >5 84 (48.3) 90 (17.1) 5.04 (3.44 – 7.37) <0,001
Total blood loss >11 91 (62.8) 52 (14.8) 2.83 (1.93 – 4.14) <0,001
Total blood loss > 21 38 (26.2) 107 (18.8) 4.43 (2.69 – 7.29) <0,001
Dialysis 27 (15.4) 148 (22.6) 7.12 (3.58 – 14.14) <0,001
Inotropie support >48 h 113 (77.4) 33 (9.1) 6.69 (4.35 – 10.28) <0,001
CardioAssist 105 (60.0) 70 (12.0) 109.93 (49.16 – 245.83) <0,001
ACT > 150 sec. 26 (21.1) 97 (21.3) 1.69 (1.01 – 2.83) 0.048
Pneumonia 17 (9.8) 156 (23.4) 6.95 (2.94 – 16.41) <0,001
Wound infection 15 (8.7) 158 (25.0) 1.02 (0.55 – 1.89) 1.000
Operative re–exploration 25 (14.5) 148 (23.1) 3.33 (1.86 – 5.97) <0,001
Pre-,intra- and postoperative data in univariaten analysis. The nominal variables are shown in absolute and percentage figures, cerebro vascular accident (CVA),
hypertension (HT), 3 vessel-coronary artery disease (3 V-CAD), left main stenosis (LMS), perimyocardial infarction (PMI), red blood cells (RBC)
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evidence that PAD is associated with an increased risk
for long-term mortality, our findings suggested that PAD
is also an independent predictor for short-term mortality
[28]. Finally, our data support that preoperative statin
treatment may have protective effects on mortality simi-
larly to recent studies by Kulik et al. and Girerd et al.
[29, 30] and prevents cardiovascular complications by
pleiotropic effects [31]. Nevertheless, optimal mortality
prediction should still be performed using established
scoring systems [32, 33]. Our study is also in consistence
with the fact that statins may reduce cytokine release
and neutrophil adhesion via a nitric oxide-mediated
mechanism and improve postoperative myocardial per-
fusion of bypassed areas [34, 35].
Conclusions
Summarizing, there are no clinically significant dif-
ferences in using cold and warm blood cardioplegia in
emergent CABG patients including long-term outcomes
regardless of the urgency status. Decreased EF, AF and
PAD remain main predictors for 30-day mortalitiy
whereas preoperative use of statins is associated with
protective effects. Warm blood cardioplegia and nor-
mothermic systemic perfusion offer safe myocardial
protection strategies in emergent CABG patients and
IWC is a cost-effective alternative. Therefore, we sug-
gest to use warm blood cardioplegia antegradely in
elective and emergent CABG procedures regardless of
the emergent status.
Limitations
This is a retrospective study with consecutive elective
and emergent patients. Even though we consecutively
matched the emergent cohort 1:2 to a control elective
Table 6 Multivariate analysis, primary endpoint: 30-days mortality
Multivariate analysis, primary endpoint: 30-days mortality (n = 45)
Variable O.R. 95 %-C.I. p-value
HLP 0.39 (0.19 – 0.79) 0.009
AF 3.33 (1.49 – 7.47) 0.003
3 V–CAD 0.36 (0.16 – 0.83) 0.016
COPD 0.26 (1.05 – 6.21) 0.038
PAD 2.51 (1.13 – 5.55) 0.023
Statin 0.38 (0.18 – 0.80) 0.010
Antiplatelet. 1.99 (0.95 – 4.17) 0.070
EF <40 % 3.66 (1.79 – 7.52) <0,001




















AF Atrial fibrillation, CVA cerebrovascular accident, HLP Hyperlipidemia,
HT Hypertension, PAD peripherial artery disease, LMS left main stenosis
Table 7 Multivariate analysis, endpoint: PMI
Multivariate analysis, endpoint: PMI (n = 175)
Variable O.R. 95 %-C.I. p-value
AF 1.79 (0.98 – 3.27) 0.060
CVA 1.68 (0.98 – 2.89) 0.059
Statin 0.66 (0.41 – 1.08) 0.101
Antiplatelet 4.79 (3.10 – 7.40) <0,001
EF < 40 % 2.04 (1.32 – 3.15) 0.001
IABP preap 3.68 (1.34 – 10.13) 0.012
Hemofiltration 3.61 (2.22 – 5.87) <0,001















OP-time after 08:00 pm
Hemofiltration
AF Atrial fibrillation, CVA cerebro vascular accident, HLP Hyperlipidemia,
HT Hypertension, PAD peripherial artery disease, LMS left main stenosis
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cohort to avoid selection bias there is still a limitation in
interpreting the results due to the use of cardioplegia de-
pending on surgeons’ preferences. There were surgeons
who routinely used cold blood cardioplegia and sur-
geons who routinely used warm blood cardioplegia
which may have influenced cross clamp times in IWC
and ICC groups.
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